MiMedx Group, Inc. (NASDAQ:MDXG) Insider Sells $14,142.36 in Stock

MiMedx Group, Inc. (NASDAQ:MDXG) insider Kimberly Maersk-Moller sold 1,759 shares of MiMedx Group stock in a transaction on Monday, March 17th. The stock was sold at an average price of $8.04, for a total transaction of $14,142.36. Following the transaction, the insider now directly owns 309,077 shares of the company’s stock, valued at $2,484,979.08. This represents a 0.57 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Kimberly Maersk-Moller also recently made the following trade(s):

• On Thursday, March 13th, Kimberly Maersk-Moller sold 4,106 shares of MiMedx Group stock. The shares were sold at an average price of $7.89, for a total value of $32,396.34.
• On Friday, February 28th, Kimberly Maersk-Moller sold 2,111 shares of MiMedx Group stock. The stock was sold at an average price of $8.40, for a total value of $17,732.40.

MiMedx Group Price Performance

Shares of NASDAQ:MDXG opened at $8.09 on Thursday. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. The stock has a market cap of $1.19 billion, a PE ratio of 14.71 and a beta of 1.97. The stock’s fifty day simple moving average is $8.40 and its two-hundred day simple moving average is $7.84. MiMedx Group, Inc. has a 1-year low of $5.47 and a 1-year high of $10.14.

MiMedx Group (NASDAQ:MDXG) last released its earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.07. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The company had revenue of $92.91 million during the quarter, compared to analyst estimates of $89.42 million. As a group, analysts forecast that MiMedx Group, Inc. will post 0.3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $13.00 price target on shares of MiMedx Group in a report on Thursday, February 27th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Phocas Financial Corp. bought a new stake in shares of MiMedx Group during the 4th quarter valued at $2,016,000. Paradigm Capital Management Inc. NY grew its holdings in MiMedx Group by 0.5% during the 4th quarter. Paradigm Capital Management Inc. NY now owns 4,686,231 shares of the company’s stock valued at $45,082,000 after buying an additional 22,131 shares in the last quarter. Virtus Fund Advisers LLC bought a new stake in shares of MiMedx Group during the fourth quarter valued at about $35,000. Virtus Investment Advisers Inc. bought a new position in shares of MiMedx Group in the fourth quarter valued at approximately $335,000. Finally, State of Wyoming grew its stake in MiMedx Group by 16.3% during the fourth quarter. State of Wyoming now owns 201,111 shares of the company’s stock valued at $1,935,000 after acquiring an additional 28,230 shares in the last quarter. Institutional investors own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.